JPRN-UMIN000009922已完成2 期
A phase II study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatment - A phase II study of SMP-105 (BCG-CWS)
Kobe Haborland Immunotherapy Clinic0 个研究点目标入组 30 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe complications(infectious disease, interstitial pneumonitis, cardiac disease, renal disease, hepatic disease, and uncontrolled diabetes mellitus). 2) Patients with autoimmune disease (scleroderma, Sjogren's syndrome, idiopathic thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis, and so on). 3) Patients who need the treatment with corticosteroids and immune-suppressive agents during this study (The use of their local and inhaled administration and non-steroidal anti-inflammatory agents is permitted). 4) Pregnant, lactating, or potentially to be pregnant. 5) Patients judged inappropriate for this study by responsible investigators.
研究者
相似试验
已完成
1 期
A phase I study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatmentMalignant tumorsJPRN-UMIN000008485Kobe Haborland Immunotherapy Clinic9
未知
2 期
A Phase 2/3 Study of S-524101 in the Patients with Perennial Allergic RhinitisAllergic rhinitisJPRN-jRCT2080221872SHIONOGI & CO., LTD.
未知
2 期
Phase 2 Double-blind Study of S-525606 in Patients with Japanese Cedar Pollinosis Using an Pollen Challenge ChamberJapanese cedar pollinosisJPRN-jRCT2080222876Shionogi & Co., Ltd.
已完成
2 期
A Phase 2, Double-blind Study of S-005151 in Patients with Acute Ischemic StrokeAcute Ischemic StrokeJPRN-jRCT2080224879SHIONOGI & CO., LTD.150
终止
1 期
Study of SBP-101 safety and tolerability in patients with previously treated pancreatic cancerPancreatic cancerACTRN12615000606583Sun BioPharma Australia Pty Ltd54